Biotech Archives - Page 41 of 795

2 minute read

Moleculin Reports Higher AML Complete Remission Rates And Durability With Additional Interim Subject Data

May 7, 9:02 AM

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Full MB-106 trial reaches 20 subjects with CRc of 45% in 1st – 7th line, with median

MBRX

3 minute read

NeuroSense Announces New Data Analysis From PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing Of Disease Progression In High-Risk ALS Patients; PrimeC Slowed Disease Progression By 43% In Pre-Specified High-Risk ALS Patients

By Benzinga Newsdesk

May 7, 8:54 AM

PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patientsConsistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigmCAMBRIDGE, Mass., May 7,

NRSN

3 minute read

Atossa Therapeutics Announces Support Of New Breast Cancer Screening Guidelines

By Benzinga Newsdesk

May 7, 8:46 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer

ATOS

3 minute read

Independent Study Results In Japan Demonstrate 0% Breast Cancer Local Recurrence 5 Years Following Treatment With IceCure’s ProSense, Adding To Continued Data Published Globally

By Benzinga Newsdesk

May 7, 8:45 AM

Study published in the peer reviewed journal Breast CancerExcellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablationStrategic distribution partner

ICCM

2 minute read

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

By Benzinga Newsdesk

May 7, 8:38 AM

CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone

NBIX

2 minute read

Precision BioSciences Announces Receipt Of FDA Fast Track Designation For ECUR-506, iECURE’s Program For The Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency

By Benzinga Newsdesk

May 7, 8:37 AM

Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene

DTIL

2 minute read

Mirum Announces Publication Of Phase 3 MARCH Data In The Lancet Demonstrating Benefits Of LIVMARLI In patients With PFIC

By Benzinga Newsdesk

May 7, 8:30 AM

- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied- Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and

MIRM

2 minute read

Oragenics Partners with Avance Clinical For Phase II Concussion Trial In Australia

By Benzinga Newsdesk

May 7, 8:22 AM

Oragenics, Inc. (NYSE:OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO),

OGEN

2 minute read

Actinium Announces KOL Webinar To Highlight Recently Announced Iomab-ACT Trial With Leading FDA Approved Commercial CAR T-Cell Therapy Being Led By The University Of Texas Southwestern

By Benzinga Newsdesk

May 7, 8:21 AM

Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinarExpansion of Iomab-ACT program

ATNM

3 minute read

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA

By Benzinga Newsdesk

May 7, 8:18 AM

ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA productImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on

IBRX